NerveTape

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

CXMT is reportedly preparing a NAND flash research and development production line in Beijing as the newly listed Chinese memory-chip company expands beyond DRAM. Representative image.

CXMT targets NAND flash as $8.6bn IPO gives China’s memory champion room to expand

Morgan Stanley’s North Haven Private Income Fund is working through another oversubscribed repurchase offer as private-credit liquidity demand remains elevated. Representative image.

Morgan Stanley private credit fund again gets withdrawal requests above its 5% limit

OpenAI reportedly expects hundreds of billions of dollars of negative free cash flow as it finances massive computing and data-centre expansion through 2030. Representative image.

OpenAI’s reported $278bn cash burn reveals the financing scale behind frontier AI

Taboola.com Ltd. has agreed to acquire finance-focused advertising technology company Dianomi plc for £19 million in guaranteed cash consideration and up to £27 million including contingent payments. Representative image.

Taboola offers up to £27m for Dianomi as AI reshapes digital advertising

A generic nerve-repair training model illustrates the technology focus of Axogen’s planned acquisition of BioCircuit Technologies. Representative image.

Axogen funds $200m BioCircuit acquisition with a $208.7m equity offering

Axogen is acquiring BioCircuit Technologies for $200 million in cash while issuing 4.91 million new shares at $42.50 to finance the deal, linking NerveTape expansion directly to shareholder dilution.

byVenkatesh

September 19, 2026

A peripheral nerve repair device and surgical instruments illustrate advances in regenerative medicine as Axogen, Inc. expands its nerve repair portfolio through the planned acquisition of BioCircuit Technologies, Inc. and its FDA-approved NerveTape technology. Representative image.

Axogen (NASDAQ: AXGN) to buy BioCircuit for $200m and prices $208.7m offering

Axogen is acquiring BioCircuit Technologies for $200 million in cash while pricing a $208.7 million equity offering, adding the FDA-approved NerveTape platform to its peripheral nerve repair portfolio.

byVenkatesh

September 12, 2026

The Latest

CXMT targets NAND flash as $8.6bn IPO gives China’s memory champion room to expand

Morgan Stanley private credit fund again gets withdrawal requests above its 5% limit

OpenAI’s reported $278bn cash burn reveals the financing scale behind frontier AI

Taboola offers up to £27m for Dianomi as AI reshapes digital advertising

Axogen funds $200m BioCircuit acquisition with a $208.7m equity offering

Axogen (NASDAQ: AXGN) to buy BioCircuit for $200m and prices $208.7m offering

CXMT targets NAND flash as $8.6bn IPO gives China’s memory champion room to expand

Morgan Stanley private credit fund again gets withdrawal requests above its 5% limit

OpenAI’s reported $278bn cash burn reveals the financing scale behind frontier AI

Taboola offers up to £27m for Dianomi as AI reshapes digital advertising

EDF plans 10 NUWARD reactors by 2035 as Europe’s SMR race moves toward deployment

Kikkoman opens $560m Wisconsin soy sauce plant as U.S. growth enters new phase

Why Howard Buffett, not Greg Abel, is becoming Berkshire Hathaway chairman

FedEx-led InPost takeover clears 89.8% acceptance as €7.8bn deal nears closing